Skye Bioscience Inc (SKYE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.86+4.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SKYE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||||||||
| R&D Expenses | — | — | — | — | 6.0 | 2.9 | 1.9 | 2.2 | 0.3 | 0.3 | 0.9 | 0.6 | 0.2 | — |
| Operating Income | (51.9) | (58.2) | (30.2) | (34.7) | (18.3) | (7.8) | (6.3) | (6.6) | (4.7) | (3.9) | (4.5) | (4.3) | (2.7) | (0.0) |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | — | 0.7 | 0.9 | 0.7 | 0.8 | 0.7 | 1.0 | 0.1 | 0.0 | — | — | — | 0.0 |
| Interest & Investment Income | 1.0 | 1.9 | 3.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | 0.0 |
| Net Interest Expenses | — | — | — | 0.8 | 0.6 | 0.8 | 0.7 | 1.0 | 0.1 | — | — | — | — | 0.0 |
| Other Non-Operating Income / Expenses | 1.4 | 2.2 | 3.6 | (2.9) | (1.2) | (0.7) | (0.3) | 7.7 | — | — | — | — | — | 0.0 |
| EBT, Incl. Unusual Items | (50.5) | (55.9) | (26.6) | (37.6) | (19.5) | (8.5) | (6.6) | 1.1 | (19.2) | (3.1) | (3.2) | (4.8) | — | (0.0) |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||||||||
| Net Income | (50.5) | (55.9) | (26.6) | (37.6) | (19.5) | (8.5) | (6.6) | 1.1 | (19.2) | (3.1) | (3.2) | (4.8) | (2.7) | (0.0) |
| Per Share | ||||||||||||||
| Basic EPS | (1.27) | (1.41) | (0.73) | (5.37) | (8.77) | (0.02) | (0.03) | 0.01 | — | (0.11) | — | — | — | — |
| Diluted EPS | (1.27) | (1.41) | (0.73) | (5.37) | (8.77) | (0.02) | (0.03) | (0.05) | — | (0.11) | — | — | — | — |
| Basic Weighted Avg Shares | 39.7 | 39.7 | 36.5 | 7.0 | 2.2 | 406.6 | 230.7 | 135.2 | — | 27.9 | — | — | — | — |
| Diluted Weighted Avg Shares | 39.7 | 39.7 | 36.5 | 7.0 | 2.2 | 406.6 | 231.4 | 169.6 | — | 27.9 | — | — | — | — |
| Supplemental | ||||||||||||||
| EBITDA | — | (57.4) | (29.9) | (34.6) | — | — | — | — | — | — | — | — | — | — |
| EBIT | (51.9) | (58.2) | (30.2) | (34.7) | (18.3) | (7.8) | (6.3) | (6.6) | (4.7) | (3.9) | (4.5) | (4.3) | (2.7) | (0.0) |
| Effective Tax Rate | — | — | — | -0.0% | -0.0% | -0.0% | -0.0% | 0.2% | -0.0% | -0.1% | -0.1% | -0.0% | — | -6.5% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.